Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ZABDENO SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ZABDENO SUSPENSION INYECTABLE

Approved

STANDARD

ZABDENO SUSPENSION INYECTABLE

Janssen-Cilag International N.V🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 25, 2021
Approval ID: 1d16243080964007
Company: Janssen-Cilag International N.V
Type: Standard

Approval Details

Approval Id: 1d16243080964007
Drug Cima Aemps Name: ZABDENO SUSPENSION INYECTABLE
Register Number: 1201444001
Holder Company Name: Janssen-Cilag International N.V
Marketing Company Name: Janssen Cilag S.A.
Holder Company Detail Path: /organization/janssen-cilag-international-nv
Authorization Date: 2021-05-25
Dosage Form: SUSPENSIÓN INYECTABLE
Dose: 0,50 ml
Route Of Administration: VÍA INTRAMUSCULAR
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Janssen-Cilag International N.V
Company Detail Path: /organization/janssen-cilag-international-nv

Company Information

Pharmaceutical Company Name: Janssen-Cilag International NV
Country Name: Belgium

Active Ingredients

VECTOR ADENOVIRUS DE TIPO 26 (AD26) QUE CODIFICA LA GLUCOPROTEINA (GP) DE LA VARIANTE MAYINGA DE ZAIRE EBOLAVIRUS

8,75 log10 unidades infecciosas (Inf.U)

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 25, 2021

Approval ID

1d16243080964007

Type

Standard

Back to CIMA-AEMPS Approvals